CVSA Adtalem Global Education Inc. Insider Trading

CVSA CEO Stephen W. Beard sells 5,291 shares ($702.4K) via pre-arranged 10b5-1 plan; stock down 14.8% from 52-week high.

Stephen W. Beard, Chairman & CEO, executed a pre-arranged 10b5-1 trading plan sale on 2026-07-13, disposing of 5,291 shares at $132.75 for a total of $702,401.41, reducing his holdings to 418,742 shares. Since this transaction is scheduled under a 10b5-1 plan adopted on 2025-12-10, it is not discretionary and therefore carries no timing signal regarding insider conviction. The company shows solid fundamentals with annual revenue growth of +12.8%, a P/E of 16.83, and $41.6M net income on $487.0M quarterly revenue. The sale reduces his stake by 1.2% and does not materially alter his substantial remaining position. This is a routine execution under a predetermined framework rather than an opportunistic market-driven decision.

CFO Robert Phelan sells 5,314 shares at $135.40 avg ($719.5K) under pre-arranged 10b5-1 plan; retains 50,492 shares post-trade.

Robert J. Phelan, Chief Financial Officer, executed 2 separate sales totaling 5,314 shares for $719,499.20 under a 10b5-1 trading plan adopted on 2025-12-12, meaning this sale was scheduled rather than discretionary. His stake in Covista Inc. decreased from 55,806 shares to 50,492 shares, representing a -9.5% reduction. The sales occurred at a blended average price of $135.40, above the current price of $131.32, though the stock remains -3.4% below its 52-week high of $135.96 and has posted strong 30-day (+4.2%) and 90-day (+17.2%) gains. Given the pre-arranged nature of the transaction, price-timing considerations do not apply to this filing; the sale reflects scheduled execution under an established plan rather than a discretionary decision tied to current valuation or company condition.

CVSA Chairman & CEO Beard sells 5,291 shares for $690,197.88 under pre-arranged 10b5-1 plan

Stephen W. Beard sold 5,291 shares across 2 separate transactions on June 10–11, 2026, at prices of $130.14 and $130.78 (blended average $130.45), generating $690,197.88 in proceeds. This sale represents a -1.2% reduction from his pre-transaction holdings of 429,324 shares, leaving him with 424,033 shares post-transaction. The sale was part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-10, meaning the transactions were scheduled rather than discretionary. At the time of sale, CVSA's stock was trading near recent highs (within 4.0% of its 52-week high of $133.74), and the company shows solid fundamentals with $487.0M quarterly revenue, $41.6M net income, and 12.8% annual revenue growth. The scheduled nature of the sale precludes any timing characterization, and the modest portfolio reduction (1.2%) does not signal a significant shift in the CEO's stake at a company showing positive earnings and growth momentum.

CFO Phelan sells 10,000 CVSA shares; first open-market sale in 36 months after stock climbs steeply.

Phelan Robert J., Covista's Chief Financial Officer, executed his first open-market sale in the past three years, disposing of a meaningful position at a price near the stock's 52-week highs. The company itself remains financially healthy—profitable with solid revenue growth—and the CFO's prior Form 4 activity consisted entirely of stock-based compensation transactions, making this an actual *market* sale rather than a routine equity grant event. The timing is noteworthy: the stock has rallied sharply over the past month, and Phelan is selling into that strength rather than accumulating, which represents a shift from his historical pattern of only receiving and holding equity awards. While a single sale does not establish a trend, it does break a 36-month pattern of inaction in the open market and warrants attention as a potential signal about how the CFO is viewing valuation or liquidity at current levels.

SVP, General Counsel Douglas G. Beck sells ~9,600 shares for $1.2M, representing his first open-market sale in three years.

Douglas G. Beck, the company's Senior Vice President, General Counsel, Corporate Secretary and Investor Relations Officer, disposed of roughly one-fifth of his holdings in a single transaction—his first open-market sale in the three-year filing window. The company itself remains solidly profitable with growing revenue, and the stock is trading modestly below its 52-week high rather than in distress. Beck's prior filing activity has been exclusively stock-compensation related (23 transactions), making this open-market sale a notable departure from his historical pattern of holding shares granted through equity plans. Without prior open-market purchase or sale activity, this is difficult to characterize as routine portfolio rebalancing; however, the data does not explain his motivation, and attributing it to concern about the company or conviction about valuation would be speculation beyond what the filing itself reveals.

Chairman & CEO Stephen Beard sells ~16K shares for $2.1M, his first open-market sale in 3 years.

Stephen Beard, Chairman & CEO of Covista, executed his first open-market sale in the past three years, disposing of roughly 3.6% of his holdings for just over $2M. The sale occurred when the stock was trading slightly below its 52-week high, having rallied meaningfully over the preceding month. Covista itself remains fundamentally sound—profitable with growing revenue and a reasonable valuation—so the sale does not reflect financial distress at the company level. Without prior open-market purchases or sales on record, this transaction marks a clear shift from Beard's documented activity, which had consisted entirely of stock-based compensation awards. The timing and size warrant attention as an indicator of the Chairman's current capital allocation priorities, though the absence of a broader pattern of insider selling provides no corroboration of concern at the board level.

Director Michael W Malafronte bought 36,036 shares at blended average $100.88 for $3.6M on 2026-03-10/11 at newly-listed CVSA.

Michael W Malafronte, a director at Covista Inc., made 3 separate purchases totaling 36,036 shares for $3,635,413.74 across two days immediately following the company's recent listing (13 trading days old as of filing). The purchases at $100.86–$100.94 represent accumulation just 3 cents below the current price of $103.84, moving his position from a net short of 10,641 shares to a net long of 25,395 shares. Given CVSA's strong recent fundamentals—revenue of $503,385,000.00, net income of $76,376,000.00, and P/E of 14.15—this substantial director purchase in the early trading window of a newly listed security merits investor attention as a potential signal of insider confidence in the valuation during the initial price-discovery phase.

Director Malafronte buys 1,200 shares of CVSA at $97.97 (first purchase); stock up to $102.04 in 2 days

Michael W. Malafronte, a director of Covista Inc., made his initial share purchase of 1,200 shares at $97.97 on 2026-03-03 for $117,564.00, building an opening position from zero holdings. Two trading days later, the stock moved to $102.04, representing a modest gain relative to purchase price. Covista presents solid fundamentals with quarterly revenue of $503,385,000.00, net income of $76,376,000.00, annual revenue growth of +12.8%, and a P/E ratio of 13.90 across a $3.5B market cap. The recent listing status (8 trading days) means this acquisition occurs in an early public-market window when director positioning decisions may reflect initial confidence in the company's public-market trajectory.

Director Kenneth J Phelan bought 508 ATGE shares at $98.29 (Nov 5); stock down 36.9% from 52-week high.

Kenneth J Phelan, a director of Adtalem Global Education Inc., purchased 508 shares at $98.29 on November 5, 2025, increasing his holdings to 18,783 shares (+2.8%). The transaction occurred as ATGE shares have declined 36.9% from the 52-week high of $154.45 and fallen 35.0% over the trailing 30 days, suggesting a significant pullback in valuation. Fundamentally, the company reported $462.3M quarterly revenue, $61.8M net income, and 12.8% annual revenue growth with a P/E of 14.01, indicating solid earnings quality despite the recent stock price deterioration. Phelan's prior open-market track record across all tickers shows 1 prior buy with a 100% 90-day win rate and 10.8% average 90-day return, though this is limited cross-ticker history and does not necessarily predict future performance at this specific ticker.

ATGE Director MALAFRONTE buys 1.0K shares at $91.85; stock down 40.3% from 52-week high, but fundamentals solid (13.25 P/E, +12.8% revenue growth).

Director Michael W. Malafronte purchased 1,000 shares of Adtalem Global Education Inc. on 2025-11-04 at $91.85, adding to a 100.4K share holding. The transaction occurs against a backdrop of significant near-term price deterioration: the stock is trading at $92.22, down 40.3% from its 52-week high of $154.45 and down 37.9% over the past 30 days. However, the company's fundamentals remain relatively intact, with a P/E of 13.25, annual revenue growth of +12.8%, and latest quarterly revenue of $462.3M with net income of $61.8M. Malafronte's prior buy at this ticker on 2025-03-07 demonstrated strong timing, with a 90d return of +46.6%, consistent with his cross-ticker track record of 100.00% 90-day win rate on buys (avg 90d return +46.6%). The purchase into an oversold price environment, paired with his demonstrated accuracy in prior ATGE trading, warrants attention from investors monitoring director-level conviction at depressed valuations.